Suppr超能文献

双心室辅助装置患者复发性左心室辅助装置血栓形成的医学管理

Medical Management of Recurrent Left Ventricular Assist Device Thrombosis in a Patient With Biventricular Assist Devices.

作者信息

Onderko Laura, Novak Sean H, Francis Sanjeev A, Shao Esther S, Afari Maxwell

机构信息

Cardiology, Maine Medical Center, Portland, USA.

Radiology, Maine Medical Center, Portland, USA.

出版信息

Cureus. 2020 Dec 3;12(12):e11872. doi: 10.7759/cureus.11872.

Abstract

Ventricular assist device (VAD) pump thrombosis is a known complication and while the preferred standard treatment is surgical pump exchange this procedure is not without risk and for some patients the risks are prohibitive. This is a case of a 68-year-old female with bilateral HeartWare ventricular assist devices (HVAD) implanted as destination therapy who presented with signs of recurrent pump thrombosis. Surgical pump exchange was deemed to confer prohibitive risk due to her underlying medical co-morbidities and therefore not an option for treatment. After careful consideration of possible options for treatment, she received systemic thrombolysis (Alteplase 5 mg IV bolus followed by 3 mg/hour infusion for 10 hours through a central line) which was successful. This case highlights, not only the rarity of bilateral VADs as destination therapy, but also demonstrates the safety and efficacy of using systemic thrombolytics in patients with bilateral HVADs for treatment of pump thrombosis.

摘要

心室辅助装置(VAD)泵血栓形成是一种已知的并发症,虽然首选的标准治疗方法是手术更换泵,但该手术并非没有风险,对一些患者来说风险过高。这是一例68岁女性患者,植入双侧HeartWare心室辅助装置(HVAD)作为终末期治疗,出现复发性泵血栓形成的迹象。由于其基础疾病,手术更换泵被认为风险过高,因此不是治疗选择。在仔细考虑了可能的治疗方案后,她接受了全身溶栓治疗(静脉推注阿替普酶5 mg,随后通过中心静脉导管以3 mg/小时的速度输注10小时),治疗成功。该病例不仅凸显了双侧VAD作为终末期治疗的罕见性,还证明了在双侧HVAD患者中使用全身溶栓药物治疗泵血栓形成的安全性和有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6920/7781569/57ffcbe0554b/cureus-0012-00000011872-i01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验